Psylo

Sydney, Australia Founded: 2021 • Age: 5 yrs
Psychedelic-derived therapeutics for mental illnesses are developed.
Request Access

About Psylo

Psylo is a company based in Sydney (Australia) founded in 2021 by Josh Ismin and Sam Banister.. Psylo has raised $14.18 million across 3 funding rounds from investors including Focalpoint Partners, Main Sequence and Lionheart Ventures. Psylo offers products and services including Neuroplastogen Therapies and Pipeline Therapies. Psylo operates in a competitive market with competitors including ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others.

  • Headquarter Sydney, Australia
  • Founders Josh Ismin, Sam Banister
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Psylo Pty Ltd
Operational Areas
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Total Equity Funding
    $14.18 M (USD)

    in 3 rounds

  • Latest Funding Round
    $8 M (USD), Seed

    Jun 03, 2024

  • Investors
  • Employee Count
    Employee Count
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Psylo

Psylo offers a comprehensive portfolio of products and services, including Neuroplastogen Therapies and Pipeline Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Treatments enhancing neuroplasticity for brain disorders.

Advanced tools for developing neurological treatments.

People of Psylo
Headcount 10-50
Employee Profiles 7
Employee Profiles
People
William Jorgensen
Lead Medicinal Chemist
People
💊 Sam Banister
Co-founder and Chief Scientific Officer
People
Lawrence P. (Larry) Wennogle, Ph.D.
Vice President Translational Research
People
Dilara Bahceci
Head of Communications

Unlock access to complete

Funding Insights of Psylo

Psylo has successfully raised a total of $14.18M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $8 million completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 3
  • Last Round Seed — $8.0M
  • First Round

    (01 Oct 2021)

  • Investors Count 13
Date Amount Transaction Name Valuation Lead Investors Investors
Jun, 2024 Amount Seed - Psylo Valuation Tenmile
Oct, 2022 Amount Seed - Psylo Valuation Main Sequence
Oct, 2021 Amount Seed - Psylo Valuation

investors

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Psylo

Psylo has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Focalpoint Partners, Main Sequence and Lionheart Ventures. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Angel
Investor Description Founded Year Domain Location
Venture capital investments are made in deep tech founders.
Founded Year Domain Location
A venture capital firm focused on transformative technologies is operated.
Founded Year Domain Location
Venture capital investments are made in health and technology sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Psylo

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Psylo

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Psylo Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Psylo

Psylo operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ATAI, COMPASS Pathways, MindMed, Beckley Psytech and Cybin, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
A biopharmaceutical company accelerating innovative mental health treatments.
domain founded_year HQ Location
Therapies for mental disorders, including psilocybin for depression, are developed.
domain founded_year HQ Location
Psychedelic-based therapies for brain health disorders are developed.
domain founded_year HQ Location
Developer of drugs for the treatment of neurological and psychiatric disorders
domain founded_year HQ Location
Psychedelic therapeutics for psychiatric disorders are developed and provided.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Frequently Asked Questions about Psylo

When was Psylo founded?

Psylo was founded in 2021.

Where is Psylo located?

Psylo is headquartered in Sydney, Australia. It is registered at Sydney, New South Wales, Australia.

Who is the current CEO of Psylo?

Josh Ismin is the current CEO of Psylo. They have also founded this company.

Is Psylo a funded company?

Psylo is a funded company, having raised a total of $14.18M across 3 funding rounds to date. The company's 1st funding round was a Seed of $1.18M, raised on Oct 01, 2021.

What does Psylo do?

Psylo was founded in 2021 in Sydney, Australia, as a developer of psychedelic-derived therapeutics targeting mental health conditions. Improved treatments against selective serotonin reuptake inhibitors are provided through these drugs, addressing issues such as treatment-resistant depression, anxiety, and addiction. Operations focus on research and development within the biotechnology sector, with activities centered in Australia.

Who are the top competitors of Psylo?

Psylo's top competitors include MindMed, COMPASS Pathways and Beckley Psytech.

What products or services does Psylo offer?

Psylo offers Neuroplastogen Therapies and Pipeline Therapies.

Who are Psylo's investors?

Psylo has 13 investors. Key investors include Focalpoint Partners, Main Sequence, Lionheart Ventures, Negev Capital, and XEIA Venture Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available